ES2062549T3 - Proteina anticoagulante. - Google Patents

Proteina anticoagulante.

Info

Publication number
ES2062549T3
ES2062549T3 ES90912756T ES90912756T ES2062549T3 ES 2062549 T3 ES2062549 T3 ES 2062549T3 ES 90912756 T ES90912756 T ES 90912756T ES 90912756 T ES90912756 T ES 90912756T ES 2062549 T3 ES2062549 T3 ES 2062549T3
Authority
ES
Spain
Prior art keywords
pct
epi
novel
sec
date
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90912756T
Other languages
English (en)
Inventor
Jesper Skou Rasmussen
Ole Juul Nordfang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES2062549T3 publication Critical patent/ES2062549T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

SE PRESENTAN NUEVOS ANALOGOS DE EPI EN DONDE SE HAN ELIMINADO UNO O MAS DE LOS RESIDUOS AMINOACIDOS DEL EPI NATIVO. UN GRUPO PREFERENTE DE LOS NUEVOS ANALOGOS DE EPI NO TIENE CAPACIDAD DE ENLACE A LA HEPARINA O TIENE MUY POCA. LOS NUEVOS ANALOGOS DE EPI SE PUEDEN UTILIZAR PARA EL TRATAMIENTO DE PACIENTES QUE PADECEN PROBLEMAS DE COAGULACION O CANCER.
ES90912756T 1989-08-18 1990-08-17 Proteina anticoagulante. Expired - Lifetime ES2062549T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK408089A DK408089D0 (da) 1989-08-18 1989-08-18 Proteiner

Publications (1)

Publication Number Publication Date
ES2062549T3 true ES2062549T3 (es) 1994-12-16

Family

ID=8129972

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90912756T Expired - Lifetime ES2062549T3 (es) 1989-08-18 1990-08-17 Proteina anticoagulante.

Country Status (9)

Country Link
US (1) US5312736A (es)
EP (1) EP0487591B1 (es)
JP (1) JP3122127B2 (es)
AT (1) ATE97918T1 (es)
AU (1) AU6285290A (es)
DE (1) DE69004966T2 (es)
DK (2) DK408089D0 (es)
ES (1) ES2062549T3 (es)
WO (1) WO1991002753A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
DK148890D0 (da) * 1990-06-19 1990-06-19 Novo Nordisk As Farmaceutisk praeparat
IL104324A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104326A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104325A (en) * 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
US5276015A (en) * 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
US20030171292A1 (en) 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
ATE187648T1 (de) * 1992-06-01 2000-01-15 Chiron Corp Zusammensetzungen enthaltend lipoprotein- associated-coagulation-inhibitor (laci) zur herstellung eines medikaments zur behandlung von akuten oder chronischen enzündungen
IL108798A0 (en) * 1993-03-02 1994-06-24 Novo Nordisk As Non-glycosylated tfpi analogues
US5455338A (en) * 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5650391A (en) * 1994-03-21 1997-07-22 Jewish Hospital Of St. Louis Methods and compositions for inhibition of hepatic clearance of tissue factor pathway inhibitor
US5824644A (en) * 1994-07-07 1998-10-20 G. D. Searle & Co. Method of attenuating arterial stenosis
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
EP0774001B1 (en) * 1994-08-05 2002-10-16 Chiron Corporation Production of tissue factor pathway inhibitor
US6090916A (en) * 1994-10-18 2000-07-18 Corvas International, Inc. Nematode-extracted serine protease inhibitors and anticoagulant proteins
US5866543A (en) * 1995-06-05 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5872098A (en) * 1995-06-05 1999-02-16 Corvas International, Inc. Nematode-extracted anticoagulant protein
CA2202351A1 (en) * 1994-10-18 1996-04-25 George Phillip Vlasuk Nematode-extracted serine protease inhibitors and anticoagulant proteins
US5866542A (en) * 1994-10-18 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5863894A (en) * 1995-06-05 1999-01-26 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5945275A (en) * 1994-10-18 1999-08-31 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
WO1997033996A2 (en) 1996-03-11 1997-09-18 Bayer Corporation Human bikunin
US5977057A (en) 1996-05-08 1999-11-02 The University Of Vermont And State Agricultural College Thrombosis prophylaxis for factor VLEIDEN carriers
WO2000037099A2 (en) * 1998-12-22 2000-06-29 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance by using a kunitz-type serine protease inhibitor
US20070140979A1 (en) * 1998-12-22 2007-06-21 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance
IL161407A0 (en) 2001-10-15 2004-09-27 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
DK2311432T3 (en) 2002-06-07 2015-02-02 Dyax Corp Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP1513929A4 (en) * 2002-06-18 2006-04-19 Zymogenetics Inc HYBRID VECTOR WITH A CYTOMEGALOVIRUS ENHANCER AND PROMOTER OF MYELOPROLIFERATIVE SARCOMA VIRUS
EP1589949B1 (en) * 2003-01-08 2008-08-13 Novartis Vaccines and Diagnostics, Inc. Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006066960A1 (en) * 2004-12-23 2006-06-29 Ludwig-Maximilians- Universität München Variant tfpi with increased anti-thrombotic activity
BRPI0613137A2 (pt) * 2005-06-24 2010-12-21 Drugrecure Aps administração em vias aéreas de proteìna c ativada em condições inflamatórias afetando o trato respiratório
EP1919499A2 (en) * 2005-07-29 2008-05-14 Universiteit van Maastricht Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor
US8828703B2 (en) 2005-12-29 2014-09-09 Dyax Corp. Protease inhibition
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
US8637454B2 (en) * 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
ES2688093T3 (es) * 2010-01-06 2018-10-30 Dyax Corp. Proteínas de unión a calicreína plasmática
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
EP3122782A4 (en) 2014-03-27 2017-09-13 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
BR112018011622A2 (pt) 2015-12-11 2018-11-27 Dyax Corp método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
CA3167336A1 (en) 2020-01-13 2021-07-22 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
IL87172A (en) * 1987-07-23 1994-12-29 Univ Washington Method of isolating highly purified tissue factor inhibitor
IL87171A (en) * 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor

Also Published As

Publication number Publication date
AU6285290A (en) 1991-04-03
EP0487591B1 (en) 1993-12-01
DE69004966T2 (de) 1994-03-24
DE69004966D1 (de) 1994-01-13
ATE97918T1 (de) 1993-12-15
WO1991002753A1 (en) 1991-03-07
DK408089D0 (da) 1989-08-18
JPH04507252A (ja) 1992-12-17
JP3122127B2 (ja) 2001-01-09
EP0487591A1 (en) 1992-06-03
DK0487591T3 (da) 1994-04-18
US5312736A (en) 1994-05-17

Similar Documents

Publication Publication Date Title
DK0487591T3 (da) Antikoagulerende protein
DE3884622D1 (de) Schmiermittelzubereitung zur behandlung von rheuma.
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
DE69005347D1 (de) Absaugkanüle für chirurgische Zwecke, insbesondere für Fettabsaugung.
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
FI946004A0 (fi) Lääketieteellisessä toimenpiteessä käytettävä trombiiniverifraktio
ES2070322T3 (es) Polipeptidos biologicamente activos basados en las secuencias del factor de crecimiento de transformacion beta.
MY102806A (en) Human interleukin-3 and muteins thereof
IT8123070A0 (it) Preparato che favorisce la coagulazione del sangue a base di proteine umani, nonche'procedimento per la preparazione
FI904951A0 (fi) Vaevnadsplasminogenaktivatorderivat.
SE8902532D0 (sv) Bestaemning av plasmaproteiner
DE3851776D1 (de) Verwendung von IGF-II zur Behandlung von Knochenkrankheiten.
DE60025008D1 (de) Bestimmung von adrenomedullin-bindenden proteinen
ES2072490T3 (es) Procedimiento para la pasteurizacion de la proteina tisular pp4.
HUP9900506A2 (hu) Protrombinszármazékok
NZ235497A (en) Peptides (possibly related to hirudin) and pharmaceutical compositions for reducing blood coagulation
ES2073391T3 (es) Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre.
DE58907930D1 (de) Amblyommin, ein neuer Wirkstoff für die Antikoagulationstherapie.
DK0482108T3 (da) Substituerede 2-imidazoliner samt fremstilling og anvendelse deraf
DK0423326T3 (da) Hidtil ukendt fysiologisk aktivt peptid og calcium-metabolisme-regulerende middel, der omfatter peptidet som effektiv besta
FI881124A7 (fi) Menetelmä proteiinin PP4 uuttamiseksi kudoksista ja sitruunahapon käyttö tähän tarkoitukseen.
IL95890A0 (en) Hiv related peptides
MX9710291A (es) Inhibidores ligantes de proteinas de fijacion con factor de crecimiento del tipo de insulina y metodos de uso para los mismos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 487591

Country of ref document: ES